BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929-1940. [PMID: 12673720 DOI: 10.1002/cncr.11266] [Cited by in Crossref: 185] [Cited by in F6Publishing: 183] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M. Reduced Expression of PTEN Protein and Its Prognostic Implications in Invasive Ductal Carcinoma of the Breast. Oncology 2005;68:398-404. [DOI: 10.1159/000086981] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.2] [Reference Citation Analysis]
2 Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS, Xia JC. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma. Cancer Lett. 2008;261:183-192. [PMID: 18160212 DOI: 10.1016/j.canlet.2007.11.019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
3 Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 2009;15:660-7. [PMID: 19147772 DOI: 10.1158/1078-0432.CCR-08-1084] [Cited by in Crossref: 84] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
4 Lu J, Hsia Y, Tu H, Hsiao Y, Yang W, Wang H, Yuh C. Liver development and cancer formation in zebrafish. Birth Defects Research Part C: Embryo Today: Reviews 2011;93:157-72. [DOI: 10.1002/bdrc.20205] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
5 Zhai S, Zhang H, Chen R, Wu J, Ai D, Tao S, Cai Y, Zhang JQ, Wang L. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma. Eur J Med Chem 2021;225:113824. [PMID: 34509167 DOI: 10.1016/j.ejmech.2021.113824] [Reference Citation Analysis]
6 Yin LR, Chen ZX, Zhang SJ, Sun BG, Liu YD, Huang HZ. Expression of phosphatase and tensin homolog deleted on chromosome ten in liver of athymic mice with hepatocellular carcinoma and the effect of Fuzheng Jiedu Decoction. World J Gastroenterol 2008; 14(1): 108-113 [PMID: 18176971 DOI: 10.3748/wjg.14.108] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
7 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Hao LS, Zhang XL, An JY, Karlin J, Tian XP, Dun ZN, Xie SR, Chen S. PTEN expression is down-regulated in liver tissues of rats with hepatic fibrosis induced by biliary stenosis. APMIS. 2009;117:681-691. [PMID: 19703128 DOI: 10.1111/j.1600-0463.2009.02515.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
9 Nakanishi Y, Shiraha H, Nishina S, Tanaka S, Matsubara M, Horiguchi S, Iwamuro M, Takaoka N, Uemura M, Kuwaki K, Hagihara H, Toshimori J, Ohnishi H, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T, Yamamoto K. Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 2011;11:3. [PMID: 21205319 DOI: 10.1186/1471-2407-11-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
10 Cotler SJ, Hay N, Xie H, Chen ML, Xu PZ, Layden TJ, Guzman G. Immunohistochemical Expression of Components of the Akt-mTORC1 Pathway is Associated with Hepatocellular Carcinoma in Patients with Chronic Liver Disease. Dig Dis Sci 2008;53:844-9. [DOI: 10.1007/s10620-007-9934-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
11 Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-3884. [PMID: 16799628 DOI: 10.1038/sj.onc.1209550] [Cited by in Crossref: 269] [Cited by in F6Publishing: 260] [Article Influence: 16.8] [Reference Citation Analysis]
12 Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 2012;5:ra24. [PMID: 22457330 DOI: 10.1126/scisignal.2002739] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 11.3] [Reference Citation Analysis]
13 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 23.4] [Reference Citation Analysis]
14 Koh YS, Kim JH, Cai H, Li L, Kim H, Kim K, Kim N, Shin BA, Lee T, Choi S, Cho CK. Dysregulated microRNAs in non-cirrhotic hepatocellular carcinoma. Genes Genom 2013;35:759-65. [DOI: 10.1007/s13258-013-0126-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. Crit Rev Oncol Hematol. 2016;105:65-72. [PMID: 27372199 DOI: 10.1016/j.critrevonc.2016.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
16 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
17 Zhang T, Zhang X, Shi W, Xu J, Fan H, Zhang S, Ni R. The DNA damage repair protein Ku70 regulates tumor cell and hepatic carcinogenesis by interacting with FOXO4. Pathology - Research and Practice 2016;212:153-61. [DOI: 10.1016/j.prp.2015.12.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
18 Khambu B, Hong H, Liu S, Liu G, Chen X, Dong Z, Wan J, Yin XM. The HMGB1-RAGE axis modulates the growth of autophagy-deficient hepatic tumors. Cell Death Dis 2020;11:333. [PMID: 32382012 DOI: 10.1038/s41419-020-2536-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med. 2014;12:273. [PMID: 25260879 DOI: 10.1186/s12967-014-0273-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
20 Mohanty S, Jensen D. Tumor Markers and Molecular Biology. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 62-81. [DOI: 10.3109/9780203092880-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Lam PYP. Gene Therapy for Hepatocellular Carcinoma. Cancer Rev A P 2003;01:281-8. [DOI: 10.1142/s021983630300027x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
23 Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G, Cervello M. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 2016;15:573-583. [PMID: 26794644 DOI: 10.1080/15384101.2016.1138183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
24 Ju H, Han K, Lee JD, Ro SW. Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy: Transgenic mouse models generated by hydrodynamic transfection. Int J Cancer 2016;138:1601-8. [DOI: 10.1002/ijc.29703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
25 Peyrou M, Bourgoin L, Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010; 16(37): 4627-4633 [PMID: 20872961 DOI: 10.3748/wjg.v16.i37.4627] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
26 McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012;3:954-87. [PMID: 23006971 DOI: 10.18632/oncotarget.652] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 21.1] [Reference Citation Analysis]
27 Karanam G, Arumugam MK. Potential anticancer effects of cyclo(-Pro-Tyr) against N-diethyl nitrosamine induced hepatocellular carcinoma in mouse through PI3K/AKT signaling. Environ Toxicol 2021. [PMID: 34726822 DOI: 10.1002/tox.23395] [Reference Citation Analysis]
28 Tu W, You L, Tsou A, Chen C. Pten Haplodeficiency Accelerates Liver Tumor Growth in miR-122a–Null Mice via Expansion of Periportal Hepatocyte-Like Cells. The American Journal of Pathology 2018;188:2688-702. [DOI: 10.1016/j.ajpath.2018.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Chen C, Changchien C, Lee C, Tung W, Hung C, Hu T, Wang J, Wang J, Lu S. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009;125:621-9. [DOI: 10.1002/ijc.24416] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
30 Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther 2008;7:2633-48. [PMID: 18790746 DOI: 10.1158/1535-7163.MCT-08-0400] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
31 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010; 2(3): 114-126 [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
32 Chang D, Wang TY, Li HC, Wei JC, Song JX. Prognostic significance of PTEN expression in esophageal squamous cell carcinoma from Linzhou City, a high incidence area of northern China. Dis Esophagus 2007;20:491-6. [PMID: 17958724 DOI: 10.1111/j.1442-2050.2007.00695.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
33 Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res. 2013;190:1-20. [PMID: 22941010 DOI: 10.1007/978-3-642-16037-0_1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
34 Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp Mol Med 2018;50:e417. [PMID: 29303510 DOI: 10.1038/emm.2017.158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
35 Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-658. [PMID: 17681183 DOI: 10.1053/j.gastro.2007.05.022] [Cited by in Crossref: 1863] [Cited by in F6Publishing: 1805] [Article Influence: 124.2] [Reference Citation Analysis]
36 Singh AK, Kumar R, Pandey AK. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med. 2018;12:9-26. [PMID: 30069430 DOI: 10.2174/2213988501812010009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
37 Shiraha H, Yamamoto K, Namba M. Human hepatocyte carcinogenesis (review). Int J Oncol. 2013;42:1133-1138. [PMID: 23426905 DOI: 10.3892/ijo.2013.1829] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 8.3] [Reference Citation Analysis]
38 Zhou X, Zhu H, Lu J. PTEN and hTERT gene expression and the correlation with human hepatocellular carcinoma. Pathology - Research and Practice 2015;211:316-9. [DOI: 10.1016/j.prp.2014.11.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
39 Alves VA, Nita ME, Carrilho FJ, Ono-Nita SK, Wakamatsu A, Lehrbach DM, de Carvalho MF, de Mello ES, Gayotto LC, da Silva LC. p53 immunostaining pattern in Brazilian patients with hepatocellular carcinoma. Rev Inst Med Trop Sao Paulo. 2004;46:25-31. [PMID: 15057330 DOI: 10.1590/S0036-46652004000100005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Li X, Wang H, Li T, Wang L, Wu X, Liu J, Xu Y, Wei W. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer 2020;44:100516. [PMID: 31836136 DOI: 10.1016/j.currproblcancer.2019.100516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
41 Morishita A, Masaki T, Yoshiji H, Nakai S, Ogi T, Miyauchi Y, Yoshida S, Funaki T, Uchida N, Kita Y, Funakoshi F, Usuki H, Okada S, Izuishi K, Watanabe S, Kurokohchi K, Kuriyama S. Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma. Hepatology 2004;40:677-86. [PMID: 15349907 DOI: 10.1002/hep.20337] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
42 Awan FM, Naz A, Obaid A, Ikram A, Ali A, Ahmad J, Naveed AK, Janjua HA. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance. Sci Rep 2017;7:11448. [PMID: 28904393 DOI: 10.1038/s41598-017-11943-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
43 Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24:288-95. [PMID: 16344319 DOI: 10.1200/JCO.2005.02.2418] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
44 Ni HM, Chao X, Yang H, Deng F, Wang S, Bai Q, Qian H, Cui Y, Cui W, Shi Y, Zong WX, Wang Z, Yang L, Ding WX. Dual Roles of Mammalian Target of Rapamycin in Regulating Liver Injury and Tumorigenesis in Autophagy-Defective Mouse Liver. Hepatology 2019;70:2142-55. [PMID: 31095752 DOI: 10.1002/hep.30770] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
45 Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009;49:1176-84. [PMID: 19072831 DOI: 10.1002/hep.22737] [Cited by in Crossref: 139] [Cited by in F6Publishing: 141] [Article Influence: 10.7] [Reference Citation Analysis]
46 Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget 2013;4:1496-506. [PMID: 24036604 DOI: 10.18632/oncotarget.1236] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
47 Reuland A, Humeny A, Magener A, Becker CM, Schiebel K. Detection of loss of heterozygosity by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based analysis of single-nucleotide polymorphisms. Clin Chem 2005;51:636-9. [PMID: 15738518 DOI: 10.1373/clinchem.2004.040899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Shu G, Yue L, Zhao W, Xu C, Yang J, Wang S, Yang X. Isoliensinine, a Bioactive Alkaloid Derived from Embryos of Nelumbo nucifera , Induces Hepatocellular Carcinoma Cell Apoptosis through Suppression of NF-κB Signaling. J Agric Food Chem 2015;63:8793-803. [DOI: 10.1021/acs.jafc.5b02993] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
49 Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM. Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells. PLoS One 2013;8:e54595. [PMID: 23355882 DOI: 10.1371/journal.pone.0054595] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
50 Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774-1783. [PMID: 15199412 DOI: 10.1172/jci200420513] [Cited by in Crossref: 51] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
51 Ding J, Gao Y, Liu R, Xu F, Liu H. Association of PTEN Polymorphisms with Susceptibility to Hepatocellular Carcinoma in a Han Chinese Population. DNA and Cell Biology 2011;30:229-34. [DOI: 10.1089/dna.2010.1126] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
52 Huard J, Mueller S, Gilles ED, Klingmüller U, Klamt S. An integrative model links multiple inputs and signaling pathways to the onset of DNA synthesis in hepatocytes. FEBS J 2012;279:3290-313. [PMID: 22443451 DOI: 10.1111/j.1742-4658.2012.08572.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
53 Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004;10:8351-6. [PMID: 15623612 DOI: 10.1158/1078-0432.CCR-04-0130] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
54 Mohamed NK, Hamad MA, Hafez MZ, Wooley KL, Elsabahy M. Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities: Nanomedicine in management of HCC. Int J Cancer 2017;140:1475-84. [DOI: 10.1002/ijc.30517] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
55 Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma. PLoS One. 2011;6:e26608. [PMID: 22028922 DOI: 10.1371/journal.pone.0026608] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
56 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
57 Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Hu TH. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol. 2008;98:349-357. [PMID: 18646041 DOI: 10.1002/jso.21109] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
58 Peruhova M, Peshevska-sekulovska M, Panayotova G, Velikova T. Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy. Gastroenterology Insights 2021;12:283-92. [DOI: 10.3390/gastroent12030025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, Chen CS. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 2009;76:957-68. [PMID: 19706731 DOI: 10.1124/mol.109.058180] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
60 Tien Kuo M, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog. 2006;45:701-709. [PMID: 16652372 DOI: 10.1002/mc.20240] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
61 Jeoung NH, Jeong JY, Kang BS. Cryptotanshinone Prevents the Binding of S6K1 to mTOR/Raptor Leading to the Suppression of mTORC1-S6K1 Signaling Activity and Neoplastic Cell Transformation. J Cancer Prev 2021;26:145-52. [PMID: 34258253 DOI: 10.15430/JCP.2021.26.2.145] [Reference Citation Analysis]
62 Khalid A, Hussain T, Manzoor S, Saalim M, Khaliq S. PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma. Tumour Biol 2017;39:101042831770575. [DOI: 10.1177/1010428317705754] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
63 Chargari C, Boige V, Deutsch É. Mécanismes de carcinogenèse hépatique : quelles pistes pour la radiosensibilisation ? Cancer/Radiothérapie 2011;15:32-8. [DOI: 10.1016/j.canrad.2010.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Levrero M, Pediconi N, Vossio S, Schinzari V, Guerrieri F, Palescandolo E. Molecular Pathogenesis. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 9-25. [DOI: 10.3109/9780203092880-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Liu Z, Sun J, Li C, Xu L, Liu J. MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-κB signaling. BMC Cancer 2021;21:1184. [PMID: 34742274 DOI: 10.1186/s12885-021-08185-w] [Reference Citation Analysis]
66 Hao LS, Zhang XL. Advances in PTEN and hepatic diseases. Shijie Huaren Xiaohua Zazhi 2008; 16(17): 1904-1911 [DOI: 10.11569/wcjd.v16.i17.1904] [Reference Citation Analysis]
67 Luo J, Lu C, Feng M, Dai L, Wang M, Qiu Y, Zheng H, Liu Y, Li L, Tang B, Xu C, Wang Y, Yang X. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish. J Exp Clin Cancer Res 2021;40:262. [PMID: 34416907 DOI: 10.1186/s13046-021-02061-y] [Reference Citation Analysis]
68 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 156] [Article Influence: 11.4] [Reference Citation Analysis]
69 Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, Changchien CS, Lee CM, Chuang JH, Tai MH. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer. 2003;98:1444-1456. [PMID: 14508832 DOI: 10.1002/cncr.11653] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 4.9] [Reference Citation Analysis]
70 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
71 He X, Zhu Z, Johnson C, Stoops J, Eaker AE, Bowen W, DeFrances MC. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res. 2008;68:5591-5598. [PMID: 18632611 DOI: 10.1158/0008-5472.CAN-08-0025] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
72 Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983, 1983.e1-1983.11. [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008] [Cited by in Crossref: 482] [Cited by in F6Publishing: 479] [Article Influence: 34.4] [Reference Citation Analysis]
73 Du Y, Zhang YW, Pu R, Han X, Hu JP, Zhang HW, Wang HY, Cao GW. Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma. Chin Med J (Engl) 2015;128:1005-13. [PMID: 25881591 DOI: 10.4103/0366-6999.155057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
74 Bai J, Yao B, Wang L, Sun L, Chen T, Liu R, Yin G, Xu Q, Yang W. lncRNA A1BG-AS1 suppresses proliferation and invasion of hepatocellular carcinoma cells by targeting miR-216a-5p. J Cell Biochem 2019;120:10310-22. [PMID: 30556161 DOI: 10.1002/jcb.28315] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
75 Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12(8): 1175-1181 [PMID: 16534867 DOI: 10.3748/wjg.v12.i8.1175] [Cited by in CrossRef: 212] [Cited by in F6Publishing: 198] [Article Influence: 13.3] [Reference Citation Analysis]
76 Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2005;41:204-6. [PMID: 15619243 DOI: 10.1002/hep.20558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
77 Kim MN, Lee SM, Kim JS, Hwang SG. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol 2019;84:809-17. [PMID: 31385002 DOI: 10.1007/s00280-019-03918-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
78 Tseng PL, Wu WH, Hu TH, Chen CW, Cheng HC, Li CF, Tsai WH, Tsai HJ, Hsieh MC, Chuang JH, Chang WT. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci Rep 2018;8:3081. [PMID: 29449614 DOI: 10.1038/s41598-018-21361-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
79 Gurusamy K. Trace element concentration in primary liver cancers--a systematic review. Biol Trace Elem Res 2007;118:191-206. [PMID: 17916922 DOI: 10.1007/s12011-007-0008-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
80 Dragoj M, Bankovic J, Sereti E, Stojanov SJ, Dimas K, Pesic M, Stankovic T. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors. Invest New Drugs 2017;35:718-32. [PMID: 28733702 DOI: 10.1007/s10637-017-0494-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
82 Miura K, Ishioka M, Minami S, Horie Y, Ohshima S, Goto T, Ohnishi H. Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice. J Biol Chem. 2016;291:11504-11517. [PMID: 27022031 DOI: 10.1074/jbc.m115.709048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
83 Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 2014;20:133-144. [PMID: 24910242 DOI: 10.1016/j.cmet.2014.05.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 13.0] [Reference Citation Analysis]
84 Ao L, Song X, Li X, Tong M, Guo Y, Li J, Li H, Cai H, Li M, Guan Q, Yan H, Guo Z. An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget 2016;7:24097-110. [PMID: 27006471 DOI: 10.18632/oncotarget.8212] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
85 Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005;26:69-76. [PMID: 15681023 DOI: 10.1016/j.tips.2004.12.011] [Cited by in Crossref: 295] [Cited by in F6Publishing: 279] [Article Influence: 17.4] [Reference Citation Analysis]
86 Liu L, Ji P, Qu N, Pu WL, Jiang DW, Liu WY, Li YQ, Shi RL. The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer. Oncol Lett 2016;12:504-12. [PMID: 27347172 DOI: 10.3892/ol.2016.4634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
87 Stankovic T, Milinkovic V, Bankovic J, Dinic J, Tanic N, Dramicanin T, Tanic N. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples. Biomedicine & Pharmacotherapy 2014;68:521-6. [DOI: 10.1016/j.biopha.2014.03.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
88 Zheng YW, Nie YZ, Taniguchi H. Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol 2013; 19(47): 8850-8860 [PMID: 24379607 DOI: 10.3748/wjg.v19.i47.8850] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
89 Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, Yaprak O, Tokat Y, Yuzer Y, Bulbul Dogusoy G. The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon. 2012;12:e7492. [PMID: 23162604 DOI: 10.5812/hepatmon.7492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
90 Hu TH, Huang CC, Wu CL, Lin PR, Liu SY, Lin JW, Chuang JH, Tai MH. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol. 2005;18:663-672. [PMID: 15605080 DOI: 10.1038/modpathol.3800336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
91 Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, Gallina P, Sergi LS, Merella S, Bulfone A, Doglioni C, von Kalle C, Kim YJ, Schmidt M, Tonon G, Naldini L, Montini E. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013;10:155-61. [PMID: 23314173 DOI: 10.1038/nmeth.2331] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
92 Hu B, Yan X, Liu F, Zhu C, Zhou H, Chen Y, Liu J, Gu X, Ni R, Zhang T. Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression. Pathol Oncol Res. 2016;22:555-565. [PMID: 26715439 DOI: 10.1007/s12253-015-0038-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
93 Caviglia JM, Schwabe RF. Mouse models of liver cancer. Methods Mol Biol 2015;1267:165-83. [PMID: 25636469 DOI: 10.1007/978-1-4939-2297-0_8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
94 Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009;284:11121-33. [PMID: 19261616 DOI: 10.1074/jbc.M806268200] [Cited by in Crossref: 72] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
95 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
96 Zuo ZH, Yu YP, Ren BG, Liu S, Nelson J, Wang Z, Tao J, Pradhan-Sundd T, Bhargava R, Michalopoulos G, Chen Q, Zhang J, Ma D, Pennathur A, Luketich J, Satdarshan Monga P, Nalesnik M, Luo JH. Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase. Hepatol Commun 2021. [PMID: 34505419 DOI: 10.1002/hep4.1724] [Reference Citation Analysis]
97 Pascale RM, Simile MM, Peitta G, Seddaiu MA, Feo F, Calvisi DF. Experimental Models to Define the Genetic Predisposition to Liver Cancer. Cancers (Basel) 2019;11:E1450. [PMID: 31569678 DOI: 10.3390/cancers11101450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
98 Cui J, Shen HM, Lim LHK. The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets. Pharmaceuticals (Basel) 2020;13:E432. [PMID: 33260729 DOI: 10.3390/ph13120432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
99 Gaba RC, Groth JV, Parvinian A, Guzman G, Casadaban LC. Gene expression in hepatocellular carcinoma: pilot study of potential transarterial chemoembolization response biomarkers. J Vasc Interv Radiol 2015;26:723-32. [PMID: 25724086 DOI: 10.1016/j.jvir.2014.12.610] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
100 Kuo H, Lin C, Lam H, Lin P, Chan H, Tseng J, Sun C, Hsu T, Wu C, Yang C, Hsu C, Tai M. PTEN overexpression attenuates angiogenic processes of endothelial cells by blockade of endothelin-1/endothelin B receptor signaling. Atherosclerosis 2012;221:341-9. [DOI: 10.1016/j.atherosclerosis.2010.08.067] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
101 Mu X, Español-Suñer R, Mederacke I, Affò S, Manco R, Sempoux C, Lemaigre FP, Adili A, Yuan D, Weber A, Unger K, Heikenwälder M, Leclercq IA, Schwabe RF. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J Clin Invest 2015;125:3891-903. [PMID: 26348897 DOI: 10.1172/JCI77995] [Cited by in Crossref: 117] [Cited by in F6Publishing: 72] [Article Influence: 16.7] [Reference Citation Analysis]
102 Rountree CB, Ding W, He L, Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells. 2009;27:290-299. [PMID: 19008348 DOI: 10.1634/stemcells.2008-0332] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
103 Guney K, Ozbilim G, Derin AT, Cetin S. Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. Auris Nasus Larynx 2007;34:481-6. [DOI: 10.1016/j.anl.2007.03.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
104 Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005. [PMID: 20639898 DOI: 10.1038/onc.2010.236] [Cited by in Crossref: 562] [Cited by in F6Publishing: 546] [Article Influence: 46.8] [Reference Citation Analysis]
105 Liu HY, Pedros C, Kong KF, Canonigo-Balancio AJ, Xue W, Altman A. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy. J Immunother Cancer 2021;9:e002792. [PMID: 34588224 DOI: 10.1136/jitc-2021-002792] [Reference Citation Analysis]
106 Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 2011;53:1558-69. [PMID: 21520171 DOI: 10.1002/hep.24232] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 6.7] [Reference Citation Analysis]
107 Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol 2015; 7(8): 1105-1111 [PMID: 26052399 DOI: 10.4254/wjh.v7.i8.1105] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
108 Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. Cancer Lett 2013;328:176-87. [PMID: 22902995 DOI: 10.1016/j.canlet.2012.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
109 Rodriguez JA, Guiteau JJ, Nazareth L, Reid JG, Goss JA, Gibbs RA, Gingras M. Sequencing the Full-Length of the Phosphatase and Tensin Homolog (PTEN) Gene in Hepatocellular Carcinoma (HCC) Using the 454 GS20 and Illumina GA DNA Sequencing Platforms. World J Surg 2009;33:647-52. [DOI: 10.1007/s00268-008-9852-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
110 Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Wooster R, Kang J, Qin CY. Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int J Mol Sci. 2012;13:9980-9991. [PMID: 22949843 DOI: 10.3390/ijms13089980] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
111 Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 2012;107:334-339. [PMID: 22713659 DOI: 10.1038/bjc.2012.230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
112 Liu Z, Sun J, Wang X, Cao Z. MicroRNA-129-5p promotes proliferation and metastasis of hepatocellular carcinoma by regulating the BMP2 gene. Exp Ther Med 2021;21:257. [PMID: 33603864 DOI: 10.3892/etm.2021.9688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Elsabahy M, Heo GS, Lim SM, Sun G, Wooley KL. Polymeric Nanostructures for Imaging and Therapy. Chem Rev 2015;115:10967-1011. [PMID: 26463640 DOI: 10.1021/acs.chemrev.5b00135] [Cited by in Crossref: 302] [Cited by in F6Publishing: 263] [Article Influence: 43.1] [Reference Citation Analysis]
114 Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497 [PMID: 24574717 DOI: 10.3748/wjg.v20.i2.486] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
115 Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2013; 19(37): 6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
116 Pan TL, Wang PW, Huang CC, Yeh CT, Hu TH, Yu JS. Network analysis and proteomic identification of vimentin as a key regulator associated with invasion and metastasis in human hepatocellular carcinoma cells. J Proteomics 2012;75:4676-92. [PMID: 22387118 DOI: 10.1016/j.jprot.2012.02.017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
117 Zucman-Rossi J, Laurent-Puig P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics. 2007;8:997-1003. [PMID: 17716233 DOI: 10.2217/14622416.8.8.997] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
118 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-665. [PMID: 24080776 DOI: 10.1038/nrgastro.2013.183] [Cited by in Crossref: 641] [Cited by in F6Publishing: 575] [Article Influence: 71.2] [Reference Citation Analysis]
119 Chen J, Liang J, Liu S, Song S, Guo W, Shen F. Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. Oncol Lett 2018;15:6857-64. [PMID: 29725418 DOI: 10.3892/ol.2018.8193] [Reference Citation Analysis]
120 Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, Zhang Y, Zhang T. Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci. 2014;59:795-806. [PMID: 24368420 DOI: 10.1007/s10620-013-2969-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
121 Zhou X, Li R, Jing R, Zuo B, Zheng Q. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively. J Cancer Res Clin Oncol 2020;146:1509-21. [PMID: 32266537 DOI: 10.1007/s00432-020-03207-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
122 Hu Y, Li Z, Guo L, Wang L, Zhang L, Cai X, Zhao H, Zha X. MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Archives of Biochemistry and Biophysics 2007;467:1-9. [DOI: 10.1016/j.abb.2007.07.027] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
123 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
124 Kovi RC, Bhusari S, Mav D, Shah RR, Ton TV, Hoenerhoff MJ, Sills RC, Pandiri AR. Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. Arch Toxicol 2019;93:2219-35. [PMID: 31278416 DOI: 10.1007/s00204-019-02505-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Wang X, He H, Lu Y, Ren W, Teng KY, Chiang CL, Yang Z, Yu B, Hsu S, Jacob ST, Ghoshal K, Lee LJ. Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog. Biochim Biophys Acta. 2015;1853:244-253. [PMID: 25447674 DOI: 10.1016/j.bbamcr.2014.10.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
127 Andjelkovic T, Bankovic J, Stojsic J, Milinkovic V, Podolski-Renic A, Ruzdijic S, Tanic N. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res 2011;157:19-28. [PMID: 21146147 DOI: 10.1016/j.trsl.2010.09.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
128 Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, Pascale RM. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 2006;1765:126-47. [PMID: 16216419 DOI: 10.1016/j.bbcan.2005.08.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 29] [Article Influence: 0.7] [Reference Citation Analysis]
129 Watanabe S, Horie Y, Kataoka E, Sato W, Dohmen T, Ohshima S, Goto T, Suzuki A. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol. 2007;22 Suppl 1:S96-S100. [PMID: 17567478 DOI: 10.1111/j.1440-1746.2006.04665.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
130 Yuan P, Zheng A, Tang Q. Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway. Cell Biol Int 2020;44:1503-13. [DOI: 10.1002/cbin.11346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Fang S, Zhang D, Weng W, Lv X, Zheng L, Chen M, Fan X, Mao J, Mao C, Ye Y, Xu M, Ji J. CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway. Biochim Biophys Acta Mol Cell Res 2020;1867:118624. [PMID: 31837982 DOI: 10.1016/j.bbamcr.2019.118624] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
132 Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. J Formos Med Assoc. 2019;118:504-513. [PMID: 30527565 DOI: 10.1016/j.jfma.2018.10.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
133 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
134 Zhang T, Wan C, Shi W, Xu J, Fan H, Zhang S, Lin Z, Ni R, Zhang X. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs. J Mol Histol 2015;46:485-97. [PMID: 26438629 DOI: 10.1007/s10735-015-9639-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
135 Buontempo F, Ersahin T, Missiroli S, Senturk S, Etro D, Ozturk M, Capitani S, Cetin-Atalay R, Neri ML. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. Invest New Drugs. 2011;29:1303-1313. [PMID: 20628892 DOI: 10.1007/s10637-010-9486-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
136 Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236-60. [PMID: 22470194 DOI: 10.18632/oncotarget.466] [Cited by in Crossref: 123] [Cited by in F6Publishing: 122] [Article Influence: 12.3] [Reference Citation Analysis]
137 Sun HX, Yang ZF, Tang WG, Ke AW, Liu WR, Li Y, Gao C, Hu B, Fu PY, Yu MC, Gao BW, Shi YH, Fan J, Xu Y. MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. J Cancer 2020;11:2476-84. [PMID: 32201518 DOI: 10.7150/jca.37748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
138 Rahmani F, Ziaeemehr A, Shahidsales S, Gharib M, Khazaei M, Ferns GA, Ryzhikov M, Avan A, Hassanian SM. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J Cell Physiol. 2020;235:4146-4152. [PMID: 31663122 DOI: 10.1002/jcp.29333] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
139 Tovar V, Villanueva A, Llovet JM. Biología celular y genética en el cáncer de hígado. Gastroenterología y Hepatología 2007;30:360-9. [DOI: 10.1157/13107573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
140 Morris SM, Carter KT, Baek JY, Koszarek A, Yeh MM, Knoblaugh SE, Grady WM. TGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene 2015;34:3273-82. [PMID: 25132272 DOI: 10.1038/onc.2014.258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
141 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
142 Chao X, Qian H, Wang S, Fulte S, Ding WX. Autophagy and liver cancer. Clin Mol Hepatol 2020;26:606-17. [PMID: 33053934 DOI: 10.3350/cmh.2020.0169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
143 Sivaramakrishnan V, Devaraj SN. Morin fosters apoptosis in experimental hepatocellular carcinogenesis model. Chem Biol Interact. 2010;183:284-292. [PMID: 19931519 DOI: 10.1016/j.cbi.2009.11.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
144 Pogribny IP. MicroRNA dysregulation during chemical carcinogenesis. Epigenomics 2009;1:281-90. [PMID: 22122703 DOI: 10.2217/epi.09.17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
145 Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther 2016;15:2553-62. [PMID: 27496136 DOI: 10.1158/1535-7163.MCT-15-0976] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
146 Cheng R, Ma R, Wang Z, Yang S, Lin X, Rong H, Ma Y. PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells. Mol Cell Biochem 2011;349:149-57. [DOI: 10.1007/s11010-010-0669-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
147 Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, Sun X, Jiang H. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett. 2011;301:75-84. [PMID: 21078540 DOI: 10.1016/j.canlet.2010.10.022] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
148 Teng YC, Shen ZQ, Kao CH, Tsai TF. Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol 2016; 22(1): 300-325 [PMID: 26755878 DOI: 10.3748/wjg.v22.i1.300] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
149 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
150 Choi JI, Cho EH, Kim SB, Kim R, Kwon J, Park M, Shin HJ, Ryu HS, Park SH, Lee KH. Promoter methylation of cysteine dioxygenase type 1: gene silencing and tumorigenesis in hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 2017;21:181-7. [PMID: 29264579 DOI: 10.14701/ahbps.2017.21.4.181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
151 Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma. Targ Oncol 2007;2:199-210. [DOI: 10.1007/s11523-007-0058-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
152 . Sex difference in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology Research 2010;40:108-10. [DOI: 10.1111/j.1872-034x.2009.00611.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
153 Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Annals of Hepatology 2008;7:192-9. [DOI: 10.1016/s1665-2681(19)31848-4] [Cited by in Crossref: 38] [Article Influence: 2.7] [Reference Citation Analysis]
154 Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-83. [PMID: 15199412 DOI: 10.1172/JCI20513] [Cited by in Crossref: 394] [Cited by in F6Publishing: 242] [Article Influence: 21.9] [Reference Citation Analysis]
155 Molina-sánchez P, Lujambio A. Experimental Models for Preclinical Research in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 333-58. [DOI: 10.1007/978-3-030-21540-8_16] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
156 Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65. [PMID: 18694380 DOI: 10.1517/14728222.12.9.1139] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.2] [Reference Citation Analysis]
157 Cheng D, Zhang L, Yang G, Zhao L, Peng F, Tian Y, Xiao X, Chung RT, Gong G. Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival. Liver Int. 2015;35:1682-1691. [PMID: 25388655 DOI: 10.1111/liv.12733] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
158 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576. [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061] [Cited by in Crossref: 3516] [Cited by in F6Publishing: 3469] [Article Influence: 234.4] [Reference Citation Analysis]
159 Mukherjee A, Samanta S, Karmakar P. Inactivation of PTEN is responsible for the survival of Hep G2 cells in response to etoposide-induced damage. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2011;715:42-51. [DOI: 10.1016/j.mrfmmm.2011.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
160 Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z. Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci. 2014;59:795-806. [PMID: 24368420 DOI: 10.1007/s10620-013-2969-2.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Lo RC, Ng IO. Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res. 2011;23:245-253. [PMID: 23359751 DOI: 10.1007/s11670-011-0245-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
162 Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol. 2011;55:1400-1408. [PMID: 21703185 DOI: 10.1016/j.jhep.2011.03.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
163 Taguchi K, Hirano I, Itoh T, Tanaka M, Miyajima A, Suzuki A, Motohashi H, Yamamoto M. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol 2014;34:900-13. [PMID: 24379438 DOI: 10.1128/MCB.01384-13] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
164 Jang K, Song YS, Jang S, Min K, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010;56:229-39. [DOI: 10.1111/j.1365-2559.2009.03468.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
165 Eritja N, Santacana M, Maiques O, Gonzalez-Tallada X, Dolcet X, Matias-Guiu X. Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model. Methods 2015;77-78:31-40. [PMID: 25461816 DOI: 10.1016/j.ymeth.2014.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
166 Liu Y, Qi X, Zeng Z, Wang L, Wang J, Zhang T, Xu Q, Shen C, Zhou G, Yang S, Chen X, Lu F. CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. Sci Rep 2017;7:2796. [PMID: 28584302 DOI: 10.1038/s41598-017-03070-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
167 Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2014;346:17-23. [PMID: 24374016 DOI: 10.1016/j.canlet.2013.12.024] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
168 Borgas DL, Gao JS, Tong M, de la Monte SM. Potential Role of Phosphorylation as a Regulator of Aspartyl-(asparaginyl)-β-hydroxylase: Relevance to Infiltrative Spread of Human Hepatocellular Carcinoma. Liver Cancer 2015;4:139-53. [PMID: 26675015 DOI: 10.1159/000367731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
169 Sui C, Xu F, Shen W, Geng L, Xie F, Dai B, Lu J, Zhang M, Yang J. Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET. Tumor Biol 2015;36:1511-8. [DOI: 10.1007/s13277-014-2679-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
170 Sugihara T, Mandai M, Koda M, Matono T, Nagahara T, Ueki M, Murawaki Y. Cowden syndrome complicated with hepatocellular carcinoma possibly originating from non-alcoholic steatohepatitis (NASH): Cowden syndrome complicated with HCC from NASH. Hepatology Research 2011;41:189-93. [DOI: 10.1111/j.1872-034x.2010.00742.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
171 Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011;3:192-222. [PMID: 21422497 DOI: 10.18632/aging.100296] [Cited by in Crossref: 366] [Cited by in F6Publishing: 367] [Article Influence: 33.3] [Reference Citation Analysis]
172 Zhong Y, Yan J, Deng M, Hu K, Yao Z, Zou Y, Xu R. Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis. Exp Biol Med (Maywood) 2013;238:866-73. [PMID: 23828588 DOI: 10.1177/1535370213494654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
173 Miura K, Ohnishi H, Morimoto N, Minami S, Ishioka M, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Isoda N, Yamamoto H. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. Cancer Sci 2019;110:771-83. [PMID: 30520543 DOI: 10.1111/cas.13902] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
174 Lee S, Kim SM, Lee RT. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal 2013;18:1165-207. [PMID: 22607099 DOI: 10.1089/ars.2011.4322] [Cited by in Crossref: 234] [Cited by in F6Publishing: 209] [Article Influence: 23.4] [Reference Citation Analysis]
175 Galicia VA, He L, Dang H, Kanel G, Vendryes C, French BA, Zeng N, Bayan JA, Ding W, Wang KS, French S, Birnbaum MJ, Rountree CB, Stiles BL. Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. Gastroenterology 2010;139:2170-82. [PMID: 20837017 DOI: 10.1053/j.gastro.2010.09.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
176 Xiao Y, Gong Q, Wang W, Liu F, Kong Q, Pan F, Zhang X, Yu C, Hu S, Fan F, Li S, Liu Y. The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma. Cancer Cell Int 2020;20:371. [PMID: 32774165 DOI: 10.1186/s12935-020-01463-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Liu L, Long H, Wu Y, Li H, Dong L, Zhong JL, Liu Z, Yang X, Dai X, Shi L, Ren M, Lin Z. HRD1-mediated PTEN degradation promotes cell proliferation and hepatocellular carcinoma progression. Cellular Signalling 2018;50:90-9. [DOI: 10.1016/j.cellsig.2018.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
178 Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol 2008; 14(11): 1720-1733 [PMID: 18350603 DOI: 10.3748/wjg.14.1720] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
179 Shiraha H, Nishina S, Yamamoto K. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem 2011;112:745-9. [PMID: 21328447 DOI: 10.1002/jcb.22973] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
180 Takahashi M, Shibutani M, Woo GH, Inoue K, Fujimoto H, Igarashi K, Kanno J, Hirose M, Nishikawa A. Cellular distributions of molecules with altered expression specific to the tumor promotion process from the early stage in a rat two-stage hepatocarcinogenesis model. Carcinogenesis. 2008;29:2218-2226. [PMID: 18586688 DOI: 10.1093/carcin/bgn135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
181 Jasphin SS, Desai D, Pandit S, Gonsalves NM, Nayak PB, Iype A. Immunohistochemical expression of phosphatase and tensin homolog in histologic gradings of oral squamous cell carcinoma. Contemp Clin Dent 2016;7:524-8. [PMID: 27994422 DOI: 10.4103/0976-237X.194111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
182 Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1:852-872. [PMID: 21994573 DOI: 10.3390/v1030852] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
183 Meguro M, Mizuguchi T, Kawamoto M, Hirata K. The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011;2011:818672. [PMID: 22187659 DOI: 10.4061/2011/818672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
184 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
185 Zolota VG, Tzelepi VN, Leotsinidis M, Zili PE, Panagopoulos ND, Dougenis D, Tsamandas AC, Scopa CD. Histologic-type specific role of cell cycle regulators in non-small cell lung carcinoma. J Surg Res 2010;164:256-65. [PMID: 19691991 DOI: 10.1016/j.jss.2009.03.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
186 Bakkar RM, Xie S, Urbauer DL, Djordjevic B, Vu K, Broaddus RR. Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma: . International Journal of Gynecological Pathology 2015;34:497-506. [DOI: 10.1097/pgp.0000000000000205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Tsuneyama K, Takano Y. Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol. 2007;15:432-440. [PMID: 18091387 DOI: 10.1097/01.pai.0000213127.96590.2d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]